prof. dr. Fritz Offner
work address
De Pintelaan 185
9000 Gent
9000 Gent
ORCID iD
0000-0003-4690-36031 – 10 of 214
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia : results of a phase II study
- 2016
- The mineralocorticoid receptor is involved in glucocorticoid resistance
- A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110
- IFM2012-03
- Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study
- Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
- Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments
- International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))
- Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL